An Open-label Study in Healthy Male Participants to Determine the Mass Balance, Absolute Bioavailability and Pharmacokinetics of Daprodustat, Administered as a Single Intravenous Microtracer (Concomitant With an Oral Dose of Non-radiolabelled Daprodustat) and a Single, Oral Radiolabelled Dose

Trial Profile

An Open-label Study in Healthy Male Participants to Determine the Mass Balance, Absolute Bioavailability and Pharmacokinetics of Daprodustat, Administered as a Single Intravenous Microtracer (Concomitant With an Oral Dose of Non-radiolabelled Daprodustat) and a Single, Oral Radiolabelled Dose

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 29 Aug 2017

At a glance

  • Drugs Daprodustat (Primary) ; Daprodustat (Primary)
  • Indications Anaemia; Diabetic foot ulcer; Perioperative ischaemia; Tendon injuries
  • Focus Pharmacokinetics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 23 Aug 2017 Planned End Date changed from 3 Oct 2017 to 20 Nov 2017.
    • 23 Aug 2017 Planned primary completion date changed from 3 Oct 2017 to 20 Nov 2017.
    • 23 Aug 2017 Planned initiation date changed from 4 Sep 2017 to 2 Oct 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top